New Healthcare and Biotech Advancements
Affimed announced promising Phase 1 data for AFM28 in treating relapsed/refractory Acute Myeloid Leukemia (R/R AML). The study, involving 29 heavily pretreated patients, demonstrated a 40% composite complete remission rate at the highest dose level (300 mg). The promising results warrant evaluation of higher dose levels. Read More
GSK announced significant overall survival (OS) results from the DREAMM-7 trial evaluating belantamab mafodotin combination therapy for multiple myeloma, demonstrating a 42% reduction in death risk over other treatments. Read More
Krystal Biotech (NASDAQ: KRYS) updated on the EMA’s review of B-VEC for DEB, with no Major Objections outstanding for full approval. CHMP opinion expected in 1Q 2025. Read More
Nanobiotix completed a Phase 1 study of NBTXR3 (JNJ-1900) in pancreatic cancer with encouraging 23 months median overall survival, advocating further trials. Read More
Eli Lilly announced positive Phase 3 results for Jaypirca (pirtobrutinib) in treating chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The BRUIN CLL-321 trial showed that pirtobrutinib reduced disease progression or death risk by 46% compared to alternative treatments. Read More
Biopharma Clinical Trials and Data
Aptose Biosciences presented promising clinical data for tuspetinib at the ASH Annual Meeting, supporting triplet therapy advancement for AML patients. Read More
Editas Medicine (NASDAQ: EDIT) provided updates from the RUBY trial for severe sickle cell disease, achieving a significant success rate in reducing vaso-occlusive events. Read More
Disc Medicine (NASDAQ: IRON) unveiled positive data from BEACON and AURORA trials at ASH 2024. Read More
CRISPR Therapeutics shared engaging findings from its Phase 1/2 trial of CTX112™, indicating potential in treating B-cell malignancies. Read More
Gilead's Kite presented long-term data for Yescarta®, showing a durable response and long-term survival after five years in patients with relapsed/refractory non-Hodgkin lymphomas. The results demonstrate significant potential for these difficult-to-treat blood cancers. Read More
Bristol Myers Squibb highlighted long-term survival data for Breyanzi in lymphoma, with promising results in their cell therapy expansion. Read More
Regeneron Pharmaceuticals showcased the potential of odronextamab in multiple lymphoma types, with remarkable response rates across studies presented at ASH. Read More
Financial Moves and Strategic Partnerships
Fortis Inc. announced the renewal of its at-the-market equity program, enabling the issuance of up to C$500 million in shares, demonstrating financial maneuverability for its capital projects. Read More
Intuit (NASDAQ: INTU) and Amazon (NASDAQ: AMZN) expanded their strategic partnership to provide financial solutions to Amazon sellers via QuickBooks integration. Read More
Butterfield (NYSE: NTB) announced a new $100 million share repurchase program running through December 2025. Read More
Millicom (Tigo) completed a series of share repurchases, acquiring 277,905 Swedish Depository Receipts, highlighting active capital management strategies. Read More
Borr Drilling secured a new contract for its premium jack-up rig 'Norve' in West Africa, adding $58 million to its revenue backlog. Read More
Corporate Earnings Releases and Projections
Planet Labs PBC (NYSE: PL) reported Q3 FY2025 financial results with record revenue of $61.3 million, reflecting an 11% YOY increase and improvements in gross margins. Read More
Toll Brothers (NYSE:TOL) announced robust FY 2024 results with net income of $475.4 million in Q4, home sales revenues increasing 10% to $3.26 billion. Read More
HealthEquity (NASDAQ: HQY) posted strong Q3 FY25 results, highlighting a 21% revenue year-over-year increase and raised FY25 guidance. Read More
Bitfarms announced a restatement of its financial statements due to a classification error, making necessary revisions without impacting the overall cash position. Read More
Tech and Sustainability Innovations
Enphase Energy (NASDAQ: ENPH) partnered with NextEnergy in the Netherlands, highlighting a drive toward innovation in energy sustainability. Read More
Otter Tail Power Company announced plans to expand solar capacity with two new facilities, contributing to their goal of 57% renewable energy generation by 2030. Read More
Recursion announced interim Phase 1 data for REC-617 as a CDK7 inhibitor, showing promising results in advanced solid tumors. Read More
SS&C Technologies Holdings signed an agreement with Insignia Financial to provide member administration services, enhancing operations and client experiences. Read More
Market Activity and Growth Outlook
Braze (BRZE) exhibited Q3 2025 performance with a 22.7% revenue increase and a robust customer base growth. Read More
C3.ai (NYSE: AI) celebrated a successful fiscal Q2 2025 with significant revenue growth and strengthened stock market presence through strategic alliances. Read More
Ocean Power Technologies (NYSE American: OPTT) secured $3 million in commitments in Latin America, underscoring promising market penetration. Read More
VICI Properties announced the pricing of a $750 million senior unsecured notes offering to fund debt repayment and future expansions. Read More
